Business Context and Reporting Period
Company: REGENXBIO Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2018
Event: Entry into a Material Definitive Agreement (Amendment to License Agreement with AveXis, Inc.)
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial performance. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Transaction Consideration:
- Upfront Payment: $80.0 million paid by AveXis upon entry into the Amendment.
- Deferred Payments: $30.0 million due on the first anniversary and $30.0 million due on the second anniversary of the effective date.
- Milestone Payments: Potential commercial milestone payments of up to $120 million.
- Royalties: Low double-digit royalty on net sales for products treating Spinal Muscular Atrophy (SMA) using AAV vectors other than AAV9.
Material Changes
The Amendment significantly expands the scope of the original 2014 License Agreement:
- License Scope Expansion: AveXis received an exclusive, worldwide commercial license (with sublicense rights) to any recombinant adeno-associated virus (AAV) vector in REGENXBIO's portfolio for SMA treatment, expanding from the original license which covered only the AAV9 vector.
- Assignment Rights: AveXis is now permitted to transfer the agreement without REGENXBIO's consent in connection with a change of control, provided the transferee agrees to the terms and pays certain fees.
- Collaboration Services: REGENXBIO may, at its sole discretion, provide collaboration services regarding SMA gene therapy development upon AveXis's written request.
Outlook, Risks, and Contingencies
Contingent Payments: In the event of a change of control of AveXis, any unpaid deferred fees (the two $30 million installments) or the first $40 million of milestone payments become immediately due.
Regulatory Disclosure: The press release associated with this filing is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Confidentiality: The Company intends to seek confidential treatment for certain portions of the Amendment.
Investor Verification Checklist
- Verify the exact effective date of the Amendment to calculate the due dates for the $30 million anniversary payments.
- Confirm the specific definition of "low double-digit royalty" in the full text of the Amendment (not provided in this summary).
- Monitor AveXis's development progress on SMA therapies to assess the likelihood of triggering the $120 million in milestone payments.
- Review the upcoming Form 10-K for the year ended December 31, 2017, where the full Amendment will be filed as an exhibit.